Page 1

PRESS RELEASE innate pharma • INNATE PHARMA REPORTS FIRST HALF 2026 BUSINESS UPDATE AND FINANCIAL RESULTS New strategic partnership with Sobi to advance lacutamab is effective , with a $ 75 million upfront payment ; TELLOMAK - 3 phase 3 initiated with FPI expected in Q1 2027 € 30 million equity financing completed to primarily support IPH4502 and preclinical ADC portfolio IPH4502 Phase 1 dose escalation and cohort enrichment enrollment completed , with initial data to be presented at ENA 2026 PACIFIC - 9 Phase 3 readout for monalizumab , led by AstraZeneca , expected in H2 2026 • Cash position of € 21.4 million¹ as of June 30 , 2026 • • Anticipated cash horizon until the end of Q1 2028 , taking into account the initial payment of $ 75 million expected from the completion of the transaction with Sobi and the proceeds from the € 30 million capital increase Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. ET Marseille , France , September 17 , 2026 , 7:00 AM CEST Innate Pharma SA ( Euronext Paris : IPH ; Nasdaq : IPHA ) ( " Innate " or the " Company " ) today reported its consolidated financial results for the six months ended June 30 , 2026. The consolidated financial statements are attached to this press release . " 2026 continues to be an important year of execution for Innate , marked by our strategic partnership with Sobi and the strengthening of our financial position , " said Jonathan Dickinson , CEO of Innate Pharma . " With the TELLOMAK - 3 Phase 3 study initiated , we are targeting the first patient in the study in Q1 2027 as we work toward a filing for accelerated approval in Sézary syndrome . Looking ahead , we will present Phase 1 data from IPH4502 at ENA 2026 and expect the PACIFIC - 9 Phase 3 readout for monalizumab by year - end , as we remain focused on delivering value for patients and shareholders . " 1 Including short term investments ( € 4.4 million ) and non - current financial instruments ( € 10.5 million ) Innate Pharma | HY 2026 Financial results | 1